These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12200382)

  • 1. A prospective study on the evolution of the T-cell repertoire in patients with Sézary syndrome treated by extracorporeal photopheresis.
    Ingen-Housz-Oro S; Bussel A; Flageul B; Michel L; Dubertret L; Kourilsky P; Gachelin G; Bachelez H; Musette P
    Blood; 2002 Sep; 100(6):2168-74. PubMed ID: 12200382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up of the T-cell clonality in Sezary patients treated by extracorporeal photopheresis using a new assay: the immunoscope technique.
    Ingen-Housz-Oro S; Bussel A; Flageul B; Dubertret L; Michel L; Gachelin G; Kourilsky P; Bachelez H; Musette P
    Transfus Apher Sci; 2003 Feb; 28(1):35-42. PubMed ID: 12620267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Total Skin Electron Beam Therapy as Part of a Multimodality Regimen for Treatment of Sézary Syndrome: Clinical, Immunologic, and Molecular Analysis.
    Durgin JS; Jariwala NN; Wysocka M; Zhang KK; Maity A; Benoit B; Plastaras JP; Lewis DJ; Rosenthal JM; Teague JE; Berg S; Del Guzzo C; Kim EJ; Vittorio C; Haun PL; Samimi SS; Villasenor-Park J; Inverso J; Clark RA; Rook AH
    JAMA Dermatol; 2021 Jan; 157(1):90-95. PubMed ID: 33112366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal photopheresis and adjuvant aerosolized granulocyte-macrophage colony-stimulating factor for Sézary syndrome.
    Bouwhuis SA; Markovic SN; McEvoy MT; Pittelkow MR
    Mayo Clin Proc; 2002 Feb; 77(2):197-200. PubMed ID: 11838656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone.
    Fraser-Andrews E; Seed P; Whittaker S; Russell-Jones R
    Arch Dermatol; 1998 Aug; 134(8):1001-5. PubMed ID: 9722731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained remission of Sézary syndrome.
    Bouwhuis SA; McEvoy MT; Davis MD
    Eur J Dermatol; 2002; 12(3):287-90. PubMed ID: 11978575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracorporeal photopheresis in Sézary syndrome: hematologic parameters as predictors of response.
    Evans AV; Wood BP; Scarisbrick JJ; Fraser-Andrews EA; Chinn S; Dean A; Watkins P; Whittaker SJ; Russell-Jones R
    Blood; 2001 Sep; 98(5):1298-301. PubMed ID: 11520774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response.
    Vonderheid EC; Bigler RD; Greenberg AS; Neukum SJ; Micaily B
    Am J Clin Oncol; 1994 Jun; 17(3):255-63. PubMed ID: 8192114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sézary syndrome treated with extracorporeal photopheresis: Report of one case].
    Molgó M; Jaque A; Vial V; Ocqueteau M; Pereira J; Chang M; González S
    Rev Med Chil; 2015 Nov; 143(11):1449-58. PubMed ID: 26757870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High clinical response rate of Sezary syndrome to immunomodulatory therapies: prognostic markers of response.
    Raphael BA; Shin DB; Suchin KR; Morrissey KA; Vittorio CC; Kim EJ; Gardner JM; Evans KG; Introcaso CE; Samimi SS; Gelfand JM; Rook AH
    Arch Dermatol; 2011 Dec; 147(12):1410-5. PubMed ID: 21844430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The sign of Leser-Trélat in association with Sézary syndrome: simultaneous disappearance of seborrheic keratoses and malignant T-cell clone during combined therapy with photopheresis and interferon alfa.
    Cohen JH; Lessin SR; Vowels BR; Benoit B; Witmer WK; Rook AH
    Arch Dermatol; 1993 Sep; 129(9):1213-5. PubMed ID: 8395792
    [No Abstract]   [Full Text] [Related]  

  • 13. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy.
    Macheiner W; Jantschitsch C; Graninger W; Pálóczy K; Bálint G; Marschalkó M; Kainberger F; Breier F; Knobler RM
    J Am Acad Dermatol; 2003 Feb; 48(2):220-6. PubMed ID: 12582392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sézary Syndrome with Nodal CD30-positive Manifestation Treated with Brentuximab Vedotin and Extracorporeal Photopheresis.
    Behle V; von Braunmühl T; Sayehli C; Gesierich A; Goebeler M; Geissinger E; Wobser M
    Acta Derm Venereol; 2017 Aug; 97(8):973-975. PubMed ID: 28512672
    [No Abstract]   [Full Text] [Related]  

  • 15. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis.
    Ni X; Maiti S; Redko A; Bijani P; Duvic M
    Photodermatol Photoimmunol Photomed; 2022 Mar; 38(2):158-168. PubMed ID: 34543492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracorporeal photochemotherapy induces a significant increase in CD36+ circulating monocytes in patients with mycosis fungoides.
    Fimiani M; Rubegni P; Pimpinelli N; Mori M; De Aloe G; Andreassi L
    Dermatology; 1997; 194(2):107-10. PubMed ID: 9094456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of circulating T-cell clones in Sezary syndrome.
    Ortonne N; Huet D; Gaudez C; Marie-Cardine A; Schiavon V; Bagot M; Musette P; Bensussan A
    Blood; 2006 May; 107(10):4030-8. PubMed ID: 16418328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with extracorporeal photopheresis, interferon-alpha, PUVA and topical corticosteroids in the management of Sézary syndrome.
    Booken N; Weiss C; Utikal J; Felcht M; Goerdt S; Klemke CD
    J Dtsch Dermatol Ges; 2010 Jun; 8(6):428-38. PubMed ID: 20180887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating CD4+CD7- lymphocyte burden and rapidity of response: predictors of outcome in the treatment of Sézary syndrome and erythrodermic mycosis fungoides with extracorporeal photopheresis.
    Stevens SR; Baron ED; Masten S; Cooper KD
    Arch Dermatol; 2002 Oct; 138(10):1347-50. PubMed ID: 12374541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extracorporeal photochemotherapy for treatment of clonal T cell proliferations].
    Plumas J; Drillat P; Jacob MC; Richard MJ; Favrot MC
    Bull Cancer; 2003; 90(8-9):763-70. PubMed ID: 14609767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.